Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ebola-proof tablet device now in use
ebola proof tablet device in use
Staff testing one of the tablets at a treatment centre in Sierra Leone.

Device promises to improve medical care in West Africa

Technology volunteers have developed an 'Ebola-proof' tablet device, which promises to improve medical care and save lives.

Medical staff working in West Africa were having to shout basic patient notes to colleagues over a fence, as even a piece of paper leaving the high-risk Ebola zone posed a risk of infection.

As well as wasting precious time, dictating notes across a fence while wearing a mask is a recipe for errors. Such basic notes did not provide medics with enough information to analyse a patient's condition over time.

When Ebola peaked in September last year, Médecins Sans Frontières appealed for help in coming up with a way for medics to record patient notes. A team of tech volunteers came together and were later joined by Google. They developed the waterproof tablet, which can be dropped in chlorine, sterilised and safely taken out of the high-risk zone.

The device can be recharged by placing it on a table, as the sharp edge on normal wire-based chargers could puncture gloves, thereby posing an infection threat.

"We had to put on full personal protective equipment to understand how difficult it was for doctors working in the high-risk zone," explained Ganesh Shankar, product manager for Google.

"We wanted to make sure the tablets would be as simple and as safe as possible to use. We got rid of all the sharp edges, pre-configured the technology so that it could be taken out of the box and used, and spent time thinking about the extreme environments that MSF staff often work in."

The tablets also allow medics to track a patient's progress by offering more complete data, including pulse and respiration rates.

MSF's Ivan Gayton, who developed the project, said: "In the longer term, if we are able to collect more and better information about our patients, we will also learn more about the disease and how best to treat it.

"Although we have just treated the largest cohort of Ebola patients in human history, we still know distressingly little about the progression of the disease.

"It will take many months to file, organise and analyse the data we have collected. Now that the technology has been developed and successfully trialled, we know that data will be instantly ready for both analysis and patient care in the future."

After a successful trial in MSF's Ebola management centres in Sierra Leone, the tablets are now in use. It is hoped the technology will be adapted for use in other humanitarian emergencies, including cholera outbreaks, nutrition crises and refugee camps.

Image © Nick Fortescue

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.